Angiogenesis research in the past two decades has contributed significantly towards
understanding the molecular pathophysiology of cancer progression and inspired target …

Breast cancer is still one of the most prevalent cancers and a leading cause of cancer death
worldwide. The key challenge with cancer treatment is the choice of the best therapeutic …

Obesity is associated with an increased risk of, and a poor prognosis for, postmenopausal
(PM) breast cancer (BC). Our goal was to determine whether diet-induced obesity (DIO) …

Background Sunitinib, a receptor tyrosine kinase (RTK) inhibitor that targets multiple
receptors such as vascular endothelial growth factor receptors (VEGFRs), was approved for …

Immunosuppressive chemoresistance is a major barrier in lung cancer treatment. However,
the immunosuppressive mechanisms responsible for lung cancer cell chemoresistance and …

Receptor tyrosine kinase (RTK) inhibitors, such as sunitinib and sorafenib, remain the first-
line drugs for the treatment of mRCC. Acquired drug resistance and metastasis are the main …

Despite significant progress in early detection and treatment, a few aggressive breast
cancers still exhibit resistance to therapy. This study aimed to identify a therapeutic target for …

Antiangiogenic therapy has shown promising results in preclinical and clinical trials.
However, tumor cells acquire resistance to this therapy by gaining ability to survive and …

The aim of this research was to evaluate the receptor tyrosine kinase inhibitor Sunitinib
combined with SN-38 in polymeric micelles for antitumor efficacy in colorectal cancer. First …

Pleiotrophin (PTN) has a moderate stimulatory effect on endothelial cell migration through α
ν β 3 integrin, while it decreases the stimulatory effect of vascular endothelial growth factor A …